Detection of the onset of ischemia and carcinogenesis by Hypoxia-Inducible transcription Factor-Based in vivo bioluminescence imaging

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Kadonosono, Tetsuya ^a   Kuchimaru, Takahiro ^a   Yamada, Shuichi ^b   Takahashi, Yumi ^c   Murakami, Atsushi ^c,i,j   Tani, Taeko ^c   Watanabe, Hitomi ^d   Tanaka, Tomoharu ^e   Hirota, Kiichi ^e   Inoue, Masahiro ^f   Tsukamoto, Tetsuya ^g,k   Toyoda, Takeshi ^g,l   Urano, Koji ^h   Machida, Kazuhiko ^h   Eto, Tomoo ^h   Ogura, Tomoyuki ^h   Tsutsumi, Hideki ^h   Ito, Mamoru ^h   Hiraoka, Masahiro ^c   Kondoh, Gen ^d   Kizaka Kondoh, Shinae ^a   more..

^a TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^b AKITA UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e KYOTO UNIVERSITY   (Japan)

^f OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^g AICHI CANCER CENTER HOSPITAL   (Japan)

^h CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

ⁱ Kobe Biomedical Laboratory   (Japan)

^j Japan SLC Inc   (Japan)

^k FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; METHYLNITROSOUREA; ALKYLATING AGENT; MESSENGER RNA; PHOTOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CARCINOGENESIS; CARCINOGENICITY; CONTROLLED STUDY; DISEASE COURSE; EMBRYO; GENE; HOL GENE; IN VIVO STUDY; ISCHEMIA; MALE; MOUSE; NEOPLASM; NONHUMAN; PAPILLOMA; TRANSGENIC MOUSE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CARCINOGEN TESTING; CHEMICALLY INDUCED DISORDER; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; HUMAN; IMAGE PROCESSING; LUMINESCENCE; METABOLISM; METHODOLOGY; ONCOGENE RAS; REAL TIME POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING;

ANIMALIA; MUS; MUS MUSCULUS;

ALKYLATING AGENTS; ANIMALS; BLOTTING, SOUTHERN; CARCINOGENICITY TESTS; FEMALE; GENES, RAS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; IMAGE PROCESSING, COMPUTER-ASSISTED; ISCHEMIA; LUMINESCENT MEASUREMENTS; LUMINESCENT PROTEINS; MALE; METHYLNITROSOUREA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; PAPILLOMA; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 80755125977     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026640     Document Type: Article

References (35)

1. Semenza GL, (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732.
2. Kaelin WG, (2005) Proline hydroxylation and gene expression. Annu Rev Biochem 74: 115-128.
3. Schofield CJ, Ratcliffe PJ, (2004) Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5: 343-354.
4. Tanimoto K, Makino Y, Pereira T, Poellinger L, (2000) Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 19: 4298-4309.
5. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL, (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 3995-4004.
6. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E, (2002) Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 277: 27975-27981.
7. Galban S, Kuwano Y, Pullmann R Jr, Martindale JL, Kim HH, et al. (2008) RNA-binding proteins HuR and PTB promote the translation of hypoxia-inducible factor 1alpha. Mol Cell Biol 28: 93-107.
8. Yang J, Ahmed A, Poon E, Perusinghe N, de Haven Brandon A, et al. (2009) Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol Cell Biol 29: 2243-2253.
9. Zhu K, Chan W, Heymach J, Wilkinson M, McConkey DJ, (2009) Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression. Cancer Res 69: 1836-1843.
10. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, et al. (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277: 29936-29944.
11. Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, et al. (2002) Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 62: 2478-2482.
12. Tang TT, Lasky LA, (2003) The forkhead transcription factor FOXO4 induces the down-regulation of hypoxia-inducible factor 1 alpha by a von Hippel-Lindau protein-independent mechanism. J Biol Chem 278: 30125-30135.
13. Liu YV, Baek JH, Zhang H, Diez R, Cole RN, et al. (2007) RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol Cell 25: 207-217.
14. Semenza GL, (2008) Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life 60: 591-597.
15. Wouters BG, Koritzinsky M, (2008) Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 8: 851-864.
16. Semenza GL, (2009) Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 19: 12-16.
17. Fels DR, Koumenis C, (2005) HIF-1alpha and p53: the ODD couple? Trends Biochem Sci 30: 426-429.
18. Harada H, Kizaka-Kondoh S, Itasaka S, Shibuya K, Morinibu A, et al. (2007) The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. Biochem Biophys Res Commun 360: 791-796.
19. Harada H, Hiraoka M, Kizaka-Kondoh S, (2002) Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res 62: 2013-2018.
20. Contag CH, (2007) In vivo pathology: seeing with molecular specificity and cellular resolution in the living body. Annu Rev Pathol 2: 277-305.
21. Greer LF 3rd, Szalay AA, (2002) Imaging of light emission from the expression of luciferases in living cells and organisms: a review. Luminescence 17: 43-74.
22. Saitoh A, Kimura M, Takahashi R, Yokoyama M, Nomura T, et al. (1990) Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene 5: 1195-1200.
23. Yamamoto S, Mitsumori K, Kodama Y, Matsunuma N, Manabe S, et al. (1996) Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice. Carcinogenesis 17: 2455-2461.
24. Yamamoto S, Urano K, Koizumi H, Wakana S, Hioki K, et al. (1998) Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. Environ Health Perspect 106 (Suppl 1): 57-69.
25. Harada H, Kizaka-Kondoh S, Hiraoka M, (2006) Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein destruction motif of HIF-1alpha containing Pro564. FEBS Lett 580: 5718-5722.
26. Kimura M, Takabuchi S, Tanaka T, Murata M, Nishi K, et al. (2008) n-Propyl gallate activates hypoxia-inducible factor 1 by modulating intracellular oxygen-sensing systems. Biochem J 411: 97-105.
27. Dame C, Fahnenstich H, Freitag P, Hofmann D, Abdul-Nour T, et al. (1998) Erythropoietin mRNA expression in human fetal and neonatal tissue. Blood 92: 3218-3225.
28. Palis J, Segel GB, (1998) Developmental biology of erythropoiesis. Blood Rev 12: 106-114.
29. Rice BW, Cable MD, Nelson MB, (2001) In vivo imaging of light-emitting probes. J Biomed Opt 6: 432-440.
30. Safran M, Kim WY, O'Connell F, Flippin L, Gunzler V, et al. (2006) Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A 103: 105-110.
31. MacDonald J, French JE, Gerson RJ, Goodman J, Inoue T, et al. (2004) The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI. Toxicol Sci 77: 188-194.
32. Long GG, Morton D, Peters T, Short B, Skydsgaard M, (2010) Alternative mouse models for carcinogenicity assessment: industry use and issues with pathology interpretation. Toxicol Pathol 38: 43-50.
33. Storer RD, Sistare FD, Reddy MV, DeGeorge JJ, (2010) An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical development. Toxicol Pathol 38: 51-61.
34. Kuchimaru T, Kadonosono T, Tanaka S, Ushiki T, Hiraoka M, et al. (2010) In vivo imaging of HIF-active tumors by an oxygen-dependent degradation protein probe with an interchangeable labeling system. PLoS One 5: e15736.
35. Kizaka-Kondoh S, Itasaka S, Zeng L, Tanaka S, Zhao T, et al. (2009) Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Clin Cancer Res 15: 3433-3441.